News

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

No Impact on Cash, Cash Equivalents and Marketable Investments, Cash Runway or Business OperationsCompany Targeting On or Before March 14,…

2 years ago

Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain…

2 years ago

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

Quarterly investor conference call and webcast scheduled for Tuesday, February 27 at 8:30 a.m. ET WESTLAKE VILLAGE, Calif., Feb. 16,…

2 years ago

Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering

FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell” or the “Company”), a clinical-stage…

2 years ago

Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share

SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”),…

2 years ago

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial…

2 years ago

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add…

2 years ago

Annual General Meeting in ALK-Abelló A/S on 14 March 2024

        ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will…

2 years ago

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that…

2 years ago

LevelJump Provides Business Update; Reflection on 2023 Accomplishments & Planned Growth for 2024

JUMP expects to announce over a 30% year-over-year increase in revenue for its wholly owned subsidiary, Canadian Teleradiology Services ("CTS").1In…

2 years ago